The effect of intermittent pneumatic compression on deep-vein thrombosis and ventilation-free days in critically ill patients with heart failure.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
20 05 2022
20 05 2022
Historique:
received:
31
10
2021
accepted:
03
05
2022
entrez:
20
5
2022
pubmed:
21
5
2022
medline:
25
5
2022
Statut:
epublish
Résumé
There are contradictory data regarding the effect of intermittent pneumatic compression (IPC) on the incidence of deep-vein thrombosis (DVT) and heart failure (HF) decompensation in critically ill patients. This study evaluated the effect of adjunctive use of IPC on the rate of incident DVT and ventilation-free days among critically ill patients with HF. In this pre-specified secondary analysis of the PREVENT trial (N = 2003), we compared the effect of adjunctive IPC added to pharmacologic thromboprophylaxis (IPC group), with pharmacologic thromboprophylaxis alone (control group) in critically ill patients with HF. The presence of HF was determined by the treating teams according to local practices. Patients were stratified according to preserved (≥ 40%) versus reduced (< 40%) left ventricular ejection fraction, and by the New York Heart Association (NYHA) classification. The primary outcome was incident proximal lower-limb DVT, determined with twice weekly venous Doppler ultrasonography. As a co-primary outcome, we evaluated ventilation-free days as a surrogate for clinically important HF decompensation. Among 275 patients with HF, 18 (6.5%) patients had prevalent proximal lower-limb DVT (detected on trial day 1 to 3). Of 257 patients with no prevalent DVT, 11/125 (8.8%) patients in the IPC group developed incident proximal lower-limb DVT compared to 6/132 (4.5%) patients in the control group (relative risk, 1.94; 95% confidence interval, 0.74-5.08, p = 0.17). There was no significant difference in ventilator-free days between the IPC and control groups (median 21 days versus 25 days respectively, p = 0.17). The incidence of DVT with IPC versus control was not different across NYHA classes (p value for interaction = 0.18), nor across patients with reduced and preserved ejection fraction (p value for interaction = 0.15). Ventilator-free days with IPC versus control were also not different across NYHA classes nor across patients with reduced or preserved ejection fraction. In conclsuion, the use of adjunctive IPC compared with control was associated with similar rate of incident proximal lower-limb DVT and ventilator-free days in critically ill patients with HF.Trial registration: The PREVENT trial is registered at ClinicalTrials.gov, ID: NCT02040103 (registered on 3 November 2013, https://clinicaltrials.gov/ct2/show/study/NCT02040103 ) and Current controlled trials, ID: ISRCTN44653506 (registered on 30 October 2013).
Identifiants
pubmed: 35595804
doi: 10.1038/s41598-022-12336-9
pii: 10.1038/s41598-022-12336-9
pmc: PMC9122920
doi:
Substances chimiques
Anticoagulants
0
Banques de données
ClinicalTrials.gov
['NCT02040103']
ISRCTN
['ISRCTN44653506']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8519Informations de copyright
© 2022. The Author(s).
Références
Blood Adv. 2018 Nov 27;2(22):3198-3225
pubmed: 30482763
Chest. 2022 Feb;161(2):418-428
pubmed: 34419428
Am J Cardiol. 2008 Apr 1;101(7):1056-9
pubmed: 18359331
Br J Anaesth. 2003 Nov;91(5):695-8
pubmed: 14570793
BMJ. 2006 Feb 11;332(7537):325-9
pubmed: 16439370
Ann Intern Med. 2011 Nov 01;155(9):625-32
pubmed: 22041951
N Engl J Med. 2019 Apr 4;380(14):1305-1315
pubmed: 30779530
Am J Med. 2008 Nov;121(11):935-42
pubmed: 18954836
J Trauma. 1996 May;40(5):710-16; discussion 716-7
pubmed: 8614068
Am J Cardiol. 2006 Sep 15;98(6):793-5
pubmed: 16950187
N Engl J Med. 2020 Jun 18;382(25):2411-2418
pubmed: 32379955
J Clin Epidemiol. 2001 Aug;54(8):810-6
pubmed: 11470390
J Am Coll Cardiol. 2015 Apr 28;65(16):1668-1682
pubmed: 25908073
Chest. 2012 Feb;141(2 Suppl):e227S-e277S
pubmed: 22315263
Blood Coagul Fibrinolysis. 2003 Jun;14(4):341-6
pubmed: 12945875
Trials. 2016 Aug 03;17(1):390
pubmed: 27488380
Circulation. 2016 Mar 1;133(9):872-80
pubmed: 26927005
Trials. 2018 Mar 15;19(1):182
pubmed: 29544550
Blood Adv. 2019 Dec 10;3(23):3898-3944
pubmed: 31794602
Am Surg. 2002 Mar;68(3):286-9; discussion 289-90
pubmed: 11893109
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Chest. 2012 Feb;141(2 Suppl):e278S-e325S
pubmed: 22315265
Neurocrit Care. 2016 Feb;24(1):47-60
pubmed: 26646118
Chest. 2012 Feb;141(2 Suppl):e195S-e226S
pubmed: 22315261
Am J Surg. 2011 Jul;202(1):16-22
pubmed: 21440888
N Engl J Med. 1999 Sep 9;341(11):793-800
pubmed: 10477777
Circ J. 2009 Aug;73(8):1513-7
pubmed: 19521019
Crit Care Med. 1999 Jun;27(6):1096-9
pubmed: 10397211
Circulation. 2004 Aug 17;110(7):874-9
pubmed: 15289368
Int J Stroke. 2014 Oct;9(7):840-55
pubmed: 25156220
Vasc Med. 2007 May;12(2):123-7
pubmed: 17615800
Lancet. 2008 Oct 4;372(9645):1231-9
pubmed: 18757089
Ulus Travma Acil Cerrahi Derg. 2005 Jan;11(1):38-42
pubmed: 15688267
Anesthesiology. 1987 Aug;67(2):266-8
pubmed: 3605756
Isr Med Assoc J. 2019 Oct;21(10):649-652
pubmed: 31599504
BMJ Open. 2021 May 20;11(5):e044103
pubmed: 34016662
J Card Fail. 2014 Oct;20(10):739-746
pubmed: 25038262
Ann Surg. 1997 Sep;226(3):306-13; discussion 313-4
pubmed: 9339937
Arch Intern Med. 2000 Dec 11-25;160(22):3415-20
pubmed: 11112234
Thromb Haemost. 2009 Jan;101(1):139-44
pubmed: 19132200